Imaging societies must respond to the growing demand for “proof of outcome” by supporting trials that provide such evidence. Accordingly, there are two different avenues to respond to the demand for value-driven medicine: First, we need to improve methods that help us measure the true clinical benefit of diagnostic tests. Value is widely defined as the ratio of benefit to cost. So although MRI-like other diagnostic tests-is performed to guide treatment, it can be very challenging to measure its clinical utility when established clinical outcome measures are used, ie, outcome measures that have been developed and refined to rate the utility of therapeutic interventions. Since diagnostic procedures take place at the very beginning, the further downstream the outcome variable is, the more confounders will occur between the diagnostic test and the end result for a patient. Thus, there is a critical need to prove its effectiveness in terms of clinical outcomes, within the context of noninvasive diagnosis and minimally invasive therapy.īy definition, however, outcomes evaluate the end result of a given diagnostic-therapeutic pathway. Unfortunately, it is also-rightly or wrongly-perceived as a cost-intensive method and an important driver of overall healthcare costs. There is little doubt that MRI is one of the most powerful diagnostic tools in contemporary clinical medicine, while offering highly advanced research opportunities and studies of (patho)physiological processes.
It is a highly versatile diagnostic tool and is an information-rich research tool for studying the mechanistic underpinning of body function and dysfunction. 1– 3 Magnetic resonance imaging (MRI) is a pivotal, diverse modality, used to evaluate a range of morphological and functional targets. This work is the result of ongoing attempts to evaluate the utility of diagnostic imaging within the larger framework of healthcare, international economic drivers, costs containment, and research.
0 kommentar(er)
